RxDoctor Payments Data

Henrico Mungcal, MD

General Practice · Long Beach, CANPI 1750326609

Payments from drug & device makers

$2,363in general payments, 2019–2025

Across 46 payments — averaging $51.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$814
  • Boehringer Ingelheim$518
  • Bayer$400
  • GSK$369
  • Amarin Pharma, Inc.$125
  • Sanofi-aventis U.S. LLC$76
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$2,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,363 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$13,042
Medicare patients
25
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate58$42,473
EliquisApixaban37$25,671
FarxigaDapagliflozin Propanediol16$16,662
TradjentaLinagliptin22$13,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,868
Combivent RespimatIpratropium/Albuterol Sulfate19$8,538
Tresiba Flextouch U-200Insulin Degludec14$7,554
Diclofenac Sodium19$7,042
Icosapent Ethyl24$6,389
BelsomraSuvorexant11$4,340
Albuterol Sulfate HfaAlbuterol Sulfate67$3,689
Humalog Kwikpen U-100Insulin Lispro25$3,665
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,452
Atorvastatin Calcium220$3,066
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Combivent Respimat$518$22,42941 claims
AstraZenecaFarxiga$814$16,66216 claims
GSKTrelegy Ellipta$369$9,86816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.

Other general practice in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →